Concepedia

Frederick L. Locke

FL

Statistics

Publications

207

Citations

25.3K

H-Index

58

Active since

2008

Affiliations

Moffitt Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Stanford University

Dana-Farber Cancer Institute

University of South Florida

Frederick L. Locke is an author at Moffitt Cancer Center specializing in oncology, immunotherapy, and medicine.

ORCID

Publications per year

2008–2025

207

Publications

207

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

, , +16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

, , +12

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Javier Muñoz, André Goy et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

, , +15

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

, , +8

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

, , +17

1–5 of 207